UK-based pharmaceutical company N4 Pharma has issued 1.5 million ordinary shares priced at £0.085 ($0.12) a share in a private placement to raise gross proceeds of £0.012m ($0.016m).
Venture capital firm Segulah Venture has agreed to invest Skr15m ($1.9m) in medical technology company Senzime.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The investment is part of Senzime’s issue of 4.1 million shares priced at Skr6 ($0.75) a share in a private placement to raise Skr25m ($3.15m).
Segulah Venture’s investment will enable Senzime to acquire capital and strengthen its ownership base.
Advokatfirman Lindahl has been appointed as the legal advisor for the transaction.
Irish specialist pharmaceutical company Allergan has filed a registration statement with the US Securities and Exchange Commission (SEC) for a public offering of securities.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAllergan will offer and sell ordinary shares, serial preferred shares, as well as purchase contracts for ordinary shares and depositary shares, and purchase units comprised of ordinary shares following the registration.
The company’s subsidiary Allergan Funding SCS (Allergan SCS) can also offer and sell senior debt securities.
The company plans to use the proceeds for general corporate purposes, including acquisitions or debt repayment.
AstraZeneca has licensed Ionis Pharmaceuticals’ antisense drug IONIS-AZ5-2.5Rx (AZD2373), which is indicated for the treatment of kidney disease.
AstraZeneca will pay $30m as an upfront payment and another $300m upon achieving development and regulatory milestones.
Based in the UK, AstraZeneca is a pharmaceutical company, while Ionis Pharmaceuticals is a biopharmaceutical company also based in the UK.
